YANGZHOU, China, July 31,
2024 /PRNewswire/ -- Meihua International Medical
Technologies Co., Ltd. ("MHUA" or the "Company") (Nasdaq: MHUA), a
reputable manufacturer and provider of Class I, II and III
disposable medical devices with operating subsidiaries in
China, today announced that its
NT-2000 surgical path analysis system successfully supported the
world's second* 5G remote robot-assisted lobectomy. This procedure,
we believe the first of its kind in China's Yangzi Delta area, was performed on
July 15, 2024, at Yangzhou University
Affiliated Hospital by a team from Shanghai Chest Hospital.
"We are honored that our cutting-edge technology could assist
the advanced 3D imaging for surgical mapping in this sophisticated
procedure," said Mr. Yongjun Liu,
Chairman of Meihua, "Despite a physical distance of over 200
kilometers between the surgical team and the patient, the operation
was executed seamlessly in just one hour, thanks to 5G technology
and the precision of the robotic surgical system. We believe that
robot-assisted surgery has made significant strides due to its
clinical effectiveness, low risk, and quick recovery times. We also
believe that successful implementations improve the quality of
medical services, allowing patients to access diverse,
personalized, and high-quality healthcare locally. We anticipate
that this innovation will not only ease the workload on medical
staff but also address disparities in medical resource distribution
across China. Moving forward,
Meihua will continue in its efforts to innovate and enhance
healthcare outcomes for patients."
The development of Meihua's robotic surgical systems is part of
the Company's strategic initiatives to increase sales of high-end
products and broaden its customer base. The Company has introduced
new overseas technologies, including minimally invasive surgical
robot systems, and established a dedicated research and development
team focused on robotic-assisted surgery (RAS) systems. The Company
believes its NT-2000 system's real-time monitoring and guidance
capabilities enable precise targeting of surgical sites, improving
the accuracy and success rates of operations. The RAS project is
being developed in conjunction with the Hope City Medical Park in
Hainan province, China. The project is expected to be completed
in the fall of 2025.
* We believe this is the World's second 5G remote robot-assisted
lobectomy, as reported by Yangzhou University Affiliated Hospital:
https://mp.weixin.qq.com/s/HuApwLs3V8rRib1nSpUMXQ and
Yangzhou Daily:
http://news.yznews.com.cn/2024-07/27/content_7674119.htm.
About Meihua International Medical Technologies Co.,
Ltd.
Meihua International Medical Technologies is a reputable
manufacturer and provider of Class I, II and III disposable medical
devices with operating subsidiaries in China. The Company manufactures and sells
Class I disposable medical devices, such as HDPE bottles for
tablets and LDPE bottles for eye drops, throat strips and anal
bags, as well as Class II and III disposable medical devices, such
as disposable identification bracelets, gynecological examination
kits, inspection kits, surgical kits, medical brushes, medical
dressing, medical catheters, uterine tissue suction tables, virus
sampling tubes, disposable infusion pumps, electronic pumps and
anesthesia puncture kits, among other products which are sold under
Meihua's own brands and are also sourced and distributed from other
manufacturers. The Company has received an international "CE"
certification and ISO 13485 system certification and has also
registered with the FDA (registration number: 3006554788) for more
than 20 Class I products. The Company has served hospitals,
pharmacies, medical institutions and medical equipment companies
for more than 30 years, providing over 1,000 types of products for
domestic sales, as well as more than120 products which are exported
to more than 30 countries internationally across Europe, North
America, South America,
Asia, Africa and Oceania.
For more information, please visit www.meihuamed.com.
Follow us on Webull: https://www.webull.com/quote/nasdaq-mhua.
Forward-Looking Statements
This press release contains forward-looking statements as
defined by the Private Securities Litigation Reform Act of 1995.
Forward-looking statements include statements concerning plans,
objectives, goals, strategies, future events or performance, and
underlying assumptions and other statements that are other than
statements of historical facts. When the Company uses words such as
"may," "will," "intend," "should," "believe," "expect,"
"anticipate," "project," "estimate" or similar expressions that do
not relate solely to historical matters, it is making
forward-looking statements. Forward-looking statements are not
guarantees of future performance and involve risks and
uncertainties that may cause the actual results to differ
materially from the Company's expectations discussed in the
forward-looking statements. These statements are subject to
uncertainties and risks including, but not limited to, the
following: the Company's ability to achieve its goals and
strategies, the Company's future business development and plans of
future business development, including its ability to successfully
develop robotic assisted surgery systems and obtain licensure and
certification for such systems, financial conditions and results of
operations, product and service demand and acceptance, reputation
and brand, the impact of competition and pricing, changes in
technology, government regulations, fluctuations in general
economic and business conditions in China, and assumptions underlying or related
to any of the foregoing and other risks contained in reports filed
by the Company with the U.S. Securities and Exchange Commission
("SEC"). For these reasons, among others, investors are cautioned
not to place undue reliance upon any forward-looking statements in
this press release. Additional factors are discussed in the
Company's filings with the SEC, including under the section
entitled "Risk Factors" in its annual report on Form 20-F, as well
as on Form 6-K and other filings, all of which are available for
review at www.sec.gov. The Company undertakes no obligation to
publicly revise these forward-looking statements to reflect events
or circumstances that arise after the date hereof.
For investor and media inquiries, please contact:
IR Department
Email: secretary@meihuamed.com
Tel: +86-0514-89800199
Christensen
Yang Song
Email: yang.song@christensencomms.com
Tel: +86-010-59001548
View original
content:https://www.prnewswire.com/news-releases/meihua-international-medical-technologies-facilitates-worlds-second-5g-remote-robot-assisted-lobectomy-302210979.html
SOURCE Meihua International Medical Technologies Co., Ltd.